Enfermedades cardiovasculares y enfermedades inflamatorias sistémicas

  1. José I. Cuende 1
  2. Ignacio J. Pérez de Diego 1
  3. Diego Godoy 2
  1. 1 Consulta de Riesgo Cardiovascular, Servicio de Medicina Interna, Complejo Asistencial Universitario de Palencia
  2. 2 Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital General de Valencia
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Year of publication: 2016

Volume: 28

Issue: 2

Pages: 94-101

Type: Article

More publications in: Clínica e investigación en arteriosclerosis


More than a century of research has shown that atherosclerosis is an inflammatory process more than an infiltrative or thrombogenic process. It has been demonstrated epidemiologically and by imaging techniques, that systemic inflammatory diseases (in particular, but not exclusively, rheumatoid arthritis and systemic lupus erythematosus) increase the atherosclerotic process, and has a demonstrated pathophysiological basis. Furthermore, treatments to control inflammatory diseases can modify the course of the atherosclerotic process. Although there are no specific scales for assessing cardiovascular risk in patients with these diseases, cardiovascular risk is high. A number of specific risk scales are being developed, that take into account specific factors such as the degree of inflammatory activity.